HC Wainwright Expects Weaker Earnings for MiNK Therapeutics

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share estimates for MiNK Therapeutics in a report released on Thursday, May 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.36) per share for the quarter, down from their prior forecast of ($0.35). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.53) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at $0.08 EPS.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.09).

MiNK Therapeutics Stock Performance

INKT opened at $7.46 on Monday. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $13.79. The firm’s 50-day simple moving average is $7.94 and its 200-day simple moving average is $7.92. The firm has a market cap of $29.74 million, a price-to-earnings ratio of -1.91 and a beta of 0.16.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.